

MATERIAL DATA SHEET

Recombinant Human His6 USP46/UAF1 Complex Cat. # E-586

Ubiquitin carboxyl-terminal hydrolase 46 (USP46) is a specialized cysteine protease with a predicted molecular weight of 42 kDa. USP46 is a member of the peptidase C19 family and USP12/USP46 subfamily, and the human protein shares 100% amino acid sequence identity with its mouse ortholog. Like USP1 and USP12, USP46 lacks appreciable activity in the absence of its co-activator UAF1. Addition of UAF1 increases the in vitro activity of USP46 10-fold or more. Biologically, USP46 has been implicated in the regulation of Alpha-Amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid receptors (AMPARs). USP46 is able to deubiquitinate AMPARs both *in vivo* and *in vitro*, and by regulating the status of AMPAR ubiquitination and turnover, this deubiquitinase may play an important role in synaptic plasticity and brain function. Recombinant USP46 contains a C-terminal 6-His tag. Recombinant UAF1 also contains a C-terminal 6-His tag. The assembled complex contains 25 μg USP46 and 45 μg UAF1, resulting in a 1:1 stoichiometry.

Prod	uct I	nfor	mat	ion

Quantity: 70 μg

MW: 43 kDa (USP46), 77 kDa (UAF1)

Source: Spodoptera frugiperda, Sf 21 (baculovirus)-derived

Contains a C-terminal 6-His tag

Accession # P62068 (USP46), Q8TAF3 (UAF1)

Stock: X mg/ml (X μM) in 50 mM HEPES pH 7.8, 100 mM NaCl, 10% (v/v) Glycerol, 1

mM TCEP

Purity: >95%, by SDS-PAGE under reducing conditions and visualized by Colloidal

Coomassie® Blue stain.



An R&D Systems Company

Use & Storage

Use:

Recombinant Human USP46/UAF1 complex is a Ubiquitin-specific deconjugating enzyme heterodimer. Reaction conditions will need to be optimized for each specific application. We recommend an initial USP46/UAF1 Complex concentration of 20-200 nM when using Ubiquitin-AMC or Ubiquitin-Rhodamine (U-550, U-555) as a substrate. *In vitro*, USP46/UAF1 complex does not efficiently hydrolyze poly-Ubiquitin chains in the absence of WDR20.

Storage:

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -70 °C as supplied.
- 3 months, -70 °C under sterile conditions after opening.

Literature

References:

- 1. Cohn, M.A. et al. (2009) J Biol Chem. 284: 5343
- 2. Huo, Y. et al. (2015) J. Neurochem. doi: 10.1111/jnc.13194.
- 3. Ohashi, M. et al. (2015) PLoS Pathog. DOI: 10.1371/journal.ppat.1004822

For research use only. Not for use in humans.

Rev. 5/17/2016 Page 2 of 2